|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBL5 |
Gene summary for UBL5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBL5 | Gene ID | 59286 |
| Gene name | ubiquitin like 5 | |
| Gene Alias | HUB1 | |
| Cytomap | 19p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | A0A024R7B0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 59286 | UBL5 | GSM4909286 | Human | Breast | IDC | 2.99e-02 | -8.74e-02 | 0.1081 |
| 59286 | UBL5 | GSM4909287 | Human | Breast | IDC | 6.61e-11 | 1.87e-01 | 0.2057 |
| 59286 | UBL5 | GSM4909288 | Human | Breast | IDC | 8.60e-05 | -2.30e-01 | 0.0988 |
| 59286 | UBL5 | GSM4909290 | Human | Breast | IDC | 1.13e-05 | 2.76e-01 | 0.2096 |
| 59286 | UBL5 | GSM4909291 | Human | Breast | IDC | 1.45e-15 | 4.00e-01 | 0.1753 |
| 59286 | UBL5 | GSM4909294 | Human | Breast | IDC | 5.13e-36 | 2.34e-01 | 0.2022 |
| 59286 | UBL5 | GSM4909296 | Human | Breast | IDC | 7.67e-32 | 2.79e-01 | 0.1524 |
| 59286 | UBL5 | GSM4909297 | Human | Breast | IDC | 5.47e-35 | 4.44e-02 | 0.1517 |
| 59286 | UBL5 | GSM4909298 | Human | Breast | IDC | 7.30e-22 | 4.29e-01 | 0.1551 |
| 59286 | UBL5 | GSM4909301 | Human | Breast | IDC | 9.51e-33 | 4.40e-01 | 0.1577 |
| 59286 | UBL5 | GSM4909302 | Human | Breast | IDC | 2.46e-12 | 2.10e-01 | 0.1545 |
| 59286 | UBL5 | GSM4909303 | Human | Breast | IDC | 7.44e-03 | 2.24e-01 | 0.0438 |
| 59286 | UBL5 | GSM4909304 | Human | Breast | IDC | 1.72e-47 | 5.59e-01 | 0.1636 |
| 59286 | UBL5 | GSM4909306 | Human | Breast | IDC | 1.27e-14 | 3.74e-01 | 0.1564 |
| 59286 | UBL5 | GSM4909309 | Human | Breast | IDC | 1.63e-04 | -1.61e-02 | 0.0483 |
| 59286 | UBL5 | GSM4909311 | Human | Breast | IDC | 9.56e-71 | 1.32e-01 | 0.1534 |
| 59286 | UBL5 | GSM4909312 | Human | Breast | IDC | 3.41e-24 | 1.17e-01 | 0.1552 |
| 59286 | UBL5 | GSM4909313 | Human | Breast | IDC | 4.38e-04 | 2.39e-02 | 0.0391 |
| 59286 | UBL5 | GSM4909315 | Human | Breast | IDC | 2.76e-55 | 5.81e-01 | 0.21 |
| 59286 | UBL5 | GSM4909316 | Human | Breast | IDC | 2.06e-45 | 7.13e-01 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000660522 | Liver | Cyst | protein targeting | 20/496 | 314/18723 | 2.88e-04 | 9.60e-03 | 20 |
| GO:005122232 | Liver | Cyst | positive regulation of protein transport | 18/496 | 303/18723 | 1.27e-03 | 3.10e-02 | 18 |
| GO:000683922 | Liver | Cyst | mitochondrial transport | 16/496 | 254/18723 | 1.27e-03 | 3.10e-02 | 16 |
| GO:190495132 | Liver | Cyst | positive regulation of establishment of protein localization | 18/496 | 319/18723 | 2.24e-03 | 4.53e-02 | 18 |
| GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
| GO:007259418 | Oral cavity | OSCC | establishment of protein localization to organelle | 284/7305 | 422/18723 | 1.50e-32 | 1.35e-29 | 284 |
| GO:000037519 | Oral cavity | OSCC | RNA splicing, via transesterification reactions | 225/7305 | 324/18723 | 5.20e-29 | 2.99e-26 | 225 |
| GO:000037719 | Oral cavity | OSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:000039819 | Oral cavity | OSCC | mRNA splicing, via spliceosome | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:003238615 | Oral cavity | OSCC | regulation of intracellular transport | 218/7305 | 337/18723 | 6.91e-22 | 1.41e-19 | 218 |
| GO:000660520 | Oral cavity | OSCC | protein targeting | 204/7305 | 314/18723 | 6.78e-21 | 1.13e-18 | 204 |
| GO:003315718 | Oral cavity | OSCC | regulation of intracellular protein transport | 155/7305 | 229/18723 | 1.05e-18 | 1.28e-16 | 155 |
| GO:190382920 | Oral cavity | OSCC | positive regulation of cellular protein localization | 179/7305 | 276/18723 | 2.20e-18 | 2.41e-16 | 179 |
| GO:190495119 | Oral cavity | OSCC | positive regulation of establishment of protein localization | 196/7305 | 319/18723 | 2.89e-16 | 2.20e-14 | 196 |
| GO:005122219 | Oral cavity | OSCC | positive regulation of protein transport | 187/7305 | 303/18723 | 7.37e-16 | 5.49e-14 | 187 |
| GO:000683918 | Oral cavity | OSCC | mitochondrial transport | 162/7305 | 254/18723 | 8.96e-16 | 6.52e-14 | 162 |
| GO:003238818 | Oral cavity | OSCC | positive regulation of intracellular transport | 134/7305 | 202/18723 | 2.82e-15 | 1.88e-13 | 134 |
| GO:007058518 | Oral cavity | OSCC | protein localization to mitochondrion | 91/7305 | 125/18723 | 1.60e-14 | 9.27e-13 | 91 |
| GO:009031610 | Oral cavity | OSCC | positive regulation of intracellular protein transport | 110/7305 | 160/18723 | 2.10e-14 | 1.19e-12 | 110 |
| GO:007265518 | Oral cavity | OSCC | establishment of protein localization to mitochondrion | 88/7305 | 120/18723 | 2.10e-14 | 1.19e-12 | 88 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBL5 | SNV | Missense_Mutation | novel | c.198G>A | p.Met66Ile | p.M66I | Q9BZL1 | protein_coding | deleterious(0.03) | benign(0.01) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| UBL5 | SNV | Missense_Mutation | c.61N>A | p.Asp21Asn | p.D21N | Q9BZL1 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |